(NewsNation) — Cannabis companies have been accused of not properly warning users of health issues related to their products, a new federal class-action lawsuit states.
The complaint, filed by Weitz & Luxenberg, targets companies in 13 states and is brought by consumers who claim the products were deceptively marketed.
“These manufacturers make representations about health benefits that are unfounded while failing to warn about health risks,” said Weitz & Luxenberg’s James Bilsborrow in a news release.
Health officials denied full access to New Jersey ICE facility: Lawsuit
Bilsborrow notes the companies’ products help with anxiety, sleep and other health problems. However, several of those supposed benefits were unfounded, according to the lawsuit.
“At the same time, these manufacturers provide no warnings about the very real potential for serious mental health harms. Cannabis-induced psychosis is just one significant danger,” Bilsborrow added.
Lawsuit links cannabis use to mental health conditions
The lawsuit also argues cannabis has been linked to mental health conditions, citing a 2017 report from the National Academy of Sciences.
“There is substantial evidence of a statistical association between cannabis use and the development of schizophrenia or other psychoses, with the highest risk among the most frequent users,” the complaint reads.
Illness sickens 12 on National Geographic cruise ship: CDC
The plaintiffs also allege the products caused economic harm, arguing they overpaid or purchased items they might not have if they had known of the risks involved.
Cannabis hyperemesis syndrome cases on the rise for years
Health care providers across the country in March reported spikes in cases of cannabinoid (or cannabis) hyperemesis syndrome, or CHS, a painful, sometimes debilitating condition linked to chronic, long-term marijuana use.
A 2025 study found that 4.4 out of 100,000 emergency department visits were diagnosed as CHS in 2016. In 2020, the rate jumped to 33.1 per 100,000 visits before dropping in 2022 to 22.3 per 100,000.
The World Health Organization added CHS to its diagnostic manual in Oct. 2025.
Copyright 2026 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
For the latest news, weather, sports, and streaming video, head to NewsNation.